LOS ANGELES, Nov. 28, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
John Caloz, Chief Financial Officer,
will present at the 11th Annual LD Micro Main Event on
December 5, 2018 at 3:00 P.M. Pacific Daylight Time at the Luxe
Sunset Boulevard Hotel in Bel-Air.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap investment space. What started
out as a newsletter highlighting unique companies has transformed
into several influential conferences annually (Invitational,
Summit, and Main Event). In excess of 1,000 people are expected to
attend the Invitational, to hear presentations from more than 200
leading microcap companies. The company's website, ldmicro.com, is
a portal that provides exclusive intraday information on the entire
sector, including the first pure microcap index (LDMi) which covers
stocks in North America with market capitalizations
between $50-$300M.
About CytRx Corporation
CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical
company with expertise in discovering and developing new
therapeutics to treat patients with cancer. CytRx's most
advanced drug conjugate, aldoxorubicin, is an improved version of
the widely used anti-cancer drug doxorubicin and has been
out-licensed to NantCell, Inc. CytRx
Corporation's website is www.cytrx.com.
About Centurion BioPharma Corporation
CytRx's wholly owned subsidiary, Centurion BioPharma
Corporation, is focused on the development of personalized medicine
that will transform solid tumor treatment. This transformational
strategy combines a portfolio of novel, anti-cancer drug candidates
that employ LADR™ (Linker Activated Drug Release) technology, a
discovery engine designed to leverage Centurion's expertise in
albumin biology and linker technology for the development of a new
class of breakthrough anti-cancer therapies with a unique albumin
companion diagnostic (ACDx) that can help identify patients who are
most likely to benefit from treatment with the LADR™-derived
therapies. A critical element of the LADR™ platform is its ability
to bind anti-cancer molecules to circulating albumin, the most
ubiquitous protein in human blood plasma, and then to release the
highly potent cytotoxic payload at the tumor site. This technology
allows for the delivery of higher doses of drug directly to the
tumor, while avoiding much of the off-target toxicity observed with
the parent molecules. Centurion BioPharma
Corporation's website
is www.centurionbiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to
obtain regulatory approval for its products that use aldoxorubicin;
the ability of NantCell, Inc., to manufacture and
commercialize products or therapies that use aldoxorubicin; the
amount, if any, of future milestone and royalty payments that we
may receive from NantCell, Inc.; the safety and efficacy
of the NANT Cancer Vaccine; the results of clinical trials
involving the NANT Cancer Vaccine; Centurion BioPharma
Corporation's ability to develop new ultra-high potency drug
candidates based on its LADR™ technology platform; our ability to
attract potential licensees; and other risks and uncertainties
described in the most recent annual and quarterly reports filed
by CytRx with the Securities and Exchange
Commission and current reports filed since the date
of CytRx's most recent annual report.
All forward-looking statements are based upon information
available to CytRx on the date the statements are first
published. CytRx undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cytrx-corporation-to-present-at-the-11th-annual-ld-micro-main-event-300756635.html
SOURCE CytRx Corporation